University College London

Stanford Rook Limited

Bioeos Limited

Ucl Biomedica Plc

Other

Stranford Rock Limited

Immodulon Therapeutics Limited

John Lawson Stanford

Graham A Rook

Graham McIntyre

Oscar Adelmo Bottasso

Cynthia Ann Stanford

Graham A W Rook

Irun R Cohen

Willem Van Eden

Alimuddin L Zumla

Cynthia A Stanford

Graham Arthur William Rook

Ayala Frenkel

Joseph Holoshitz

Graham Mcintyre

Graham Arthur Rook

The present invention relates to a method of producing rough strains of a bacterium, such as, said method comprising exposing said bacterium to a sulfone and/or sulfonamide (such as 4,4'-Diaminodiphenyl sulfone or an analogue thereof). A rough strain ofproducible by said method and uses thereof. In particular, uses of a rough strain ofdeposited under the Budapest Treaty at the NCTC with the accession number NCTC 13365.

Method of producing rough strains of bacteria and uses thereof

Use of whole cells of bacteria from the genera of aerobic organisms in the order of Actinomycetales in the manufacture of a medicament for the treatment or prevention of Type II diabetes and/or obesity and methods of treating or preventing Type II diabetes and/or obesity in a subject by administering an effective amount of a composition comprising a whole cell of a bacterium from a genera of aerobic organisms in the order of Actinomycetales to said subject. Preferably the bacteria is from one or more of the following genera for example:and

Method of treating and/or preventing type II diabetes using Actinomycetales

An immune modulator composition and/or pharmaceutical composition comprising a whole cell of a bacterium from the generaand, wherein said immune modulator composition in use modifies a cellular immune response.

Whole bacterial cells as immune modulator

This invention relates to a method for treating or preventing (including immunising against) post-wearing multisystemic wasting syndrome (PMWS) and/or porcine dermatitis and nephropathy syndrome (PDNS) in a subject comprising administering an effective amount of a pharmaceutical composition or immune modulator composition comprising a whole cell of a bacterium from one or more of the generaand, to said subject. In addition the method relates to the use of an immune modulator composition or a pharmaceutical composition comprising a whole cell of a bacterium from the generaand, in the manufacture of a medicament for the treatment or prevention of post-wearing multisystemic wasting syndrome (PMWS) and/or porcine dermatitis and nephropathy syndrome (PDNS).

Composition for increasing the survival to slaughter rate of piglets

Use of an immune modulator composition and/or pharmaceutical composition comprising a whole cell of a bacterium from the generaand, for use in the manufacture of a medicament for the treatment of an autoimmune disease or autoimmune disorder, including certain vascular disorders.

Immune modulator

Antigenic and/or immunogenic material derived fromis used to down-regulate Th2 activity of the immune system without up-regulation of Th1 activity. Disorders such as Chronic Fatigue Syndrome, Gulf War Syndrome and Total Allergy Syndrome are treated. The material preferably comprises deadcells in a composition which does not include a non-antigen, immunogen or allergen.

Mycobacterium vaccae for down-regulation of the Th2 activity of the immune system

The present invention provides the use of an preparation for the manufacture of a medicament for use in the treatment of a chronic viral infection, excluding an HIV infection. Chronic viral infections include HPV infection, such as HPV infection associated with cervical dysplasia, herpes virus infection, subacute sclerosing pan-encephalitis and hepatitis virus infection.

Treatment of chronic viral infections with M. vaccae

Antigenic and/or immunoregulatory material derived from is useful in the prophylaxis or therapy of AIDS with or without associated tuberculosis.

Prophylactic and therapeutic method

Antigenic and/or immunoregulatory material derived from,is useful for delaying the onset of AIDS with or without associated tuberculosis.

Method for delaying the onset of AIDS

Immunotherapeutic agent and its use

Mycobacterium vaccae for treatment of long term autoimmune conditions

Immunoregulatory material derived from Mycobacterium vaccae, especially dead cells of M. vaccae, are useful for the treatment of pathological conditions (other than mycobacterial disease and arthritic disease) in a patient in which the patient's IgG shows an abnormally high proportion of agalactosyl IgG and for the treatment of chronic inflammatory disorders (other than an arthritic disease) caused or accompanied by an abnormally high release from macrophages of interleukin-6 and/or tumor necrosis factor.

Treatment of psoriasis using dead cells of Mycobacterium vaccae

Immunoregulatry material from a mycobacterium other an M. tuberculosis, especially killed cells of M. vaccae, is an advantageous adjuvant for administration with antigens (including allergens).

Growing community of inventors

Nr Tonbridge, United Kingdom

John Lawson Stanford